⏳ Fetching live dividend data...
Home › Calculator › AMGN Dividend Calculator 2026
Amgen Inc. · NASDAQ
Price: $355.30 · Annual div: $9.66/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in AMGN → $1.14M in 10 years · $1,429.35/month
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime.
Ready to invest? Open AMGN position with:
Real after-tax yield depends on where you live and how you hold AMGN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.72% | -0.08% | $272 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.31% | -0.49% | $231 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.18% | -0.62% | $218 / yr |
| 🇬🇧 UK ISA | 0% | 2.72% | -0.08% | $272 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.48% | -0.32% | $248 / yr |
| 🇨🇦 TFSA | 0% | 2.72% | -0.08% | $272 / yr |
| 🇨🇦 CA Taxable | 25% | 2.04% | -0.76% | $204 / yr |
| 🇦🇺 Super (pension) | 15% | 2.31% | -0.49% | $231 / yr |
| 🇦🇺 AU Taxable | 30% | 1.90% | -0.90% | $190 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.00% | -0.80% | $200 / yr |
| 🇫🇷 FR Taxable | 30% | 1.90% | -0.90% | $190 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $9.66/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
AMGN pays quarterly — 4 times per year. Next ex-div: TBD.
How AMGN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for AMGN sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| F-InKind | 2026-05-02 | 697 | $329.82 | $229.9K | ||
| F-InKind | 2026-05-02 | 641 | $329.82 | $211.4K | ||
| F-InKind | 2026-05-02 | 746 | $329.82 | $246.0K | ||
| F-InKind | 2026-05-02 | 687 | $329.82 | $226.6K | ||
| F-InKind | 2026-05-02 | 167 | $329.82 | $55.1K | ||
| F-InKind | 2026-05-02 | 198 | $329.82 | $65.3K | ||
| F-InKind | 2026-05-02 | 117 | $329.82 | $38.6K | ||
| F-InKind | 2026-05-02 | 108 | $329.82 | $35.6K | ||
| F-InKind | 2026-05-02 | 126 | $329.82 | $41.6K | ||
| F-InKind | 2026-05-02 | 116 | $329.82 | $38.3K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the AMGN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →